Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 11, 2025 05:52 ET | Source: Vantage Biosciences

Vantage Biosciences Doses First Patient in Phase 2 Clinical Study of Oral VX-01 for Non-Proliferative Diabetic Retinopathy

Vantage Biosciences, a clinical-stage biotechnology company advancing innovative therapies for diabetic eye diseases, announces first NPDR patient dosed.
July 28, 2023 06:53 ET | Source: Research and Markets

Growing Geriatric Population and Rising Prevalence of Diabetes Fuel Ophthalmic Viscosurgical Devices Market 2023-2028

Dublin, July 28, 2023 (GLOBE NEWSWIRE) -- The "Ophthalmic Viscosurgical Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023-2028)" report has been added to ...
July 26, 2023 04:51 ET | Source: Vantage Biosciences

ALSA Ventures launches Vantage Biosciences to treat Diabetic Eye Disease

Diabetic eye diseases are the leading cause of blindness in the working age populationVX-01 is an oral therapy – current treatments require regular invasive intravitreal injections and intervene at...
November 06, 2017 08:30 ET | Source: Vision Source

Rise of Diabetes Epidemic Leads to Innovations in Diabetic Patient Care Nationwide

Kingwood, Texas, Nov. 06, 2017 (GLOBE NEWSWIRE) -- The 2017 National Diabetes Statistics Report, published by the Centers for Disease Control and Prevention, found that 30.3 million people are...